Comprehensive NeuroScience Announces New Company Name
Comprehensive NeuroScience
is pleased to announce its plans to roll out the new company name,
Comprehensive Clinical Development
. Under its new name, Comprehensive Clinical Development will continue to deliver CRO services in partnership with quality sponsors.
Comprehensive Clinical Development offers full-service capabilities and therapeutic expertise in numerous indications, including, but not limited to, CNS, dermatology, diabetes, infectious disease, obesity, and postmenopausal women, and collects early efficacy data across these populations.
Offering CRO services both of developmental and clinical conduct, Comprehensive Clinical Development leverages the diversity of its service networks to provide biopharmaceutical clients with exceptional quality and cost-effective trial management. Along with early and late phase site clinical conduct, Comprehensive Clinical Development provides a full range of services from protocol writing through final clinical study reporting.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
